This assay is based on humanized basophils/mast cells, the RBL-2H3 cell line, that like mast cells and basophils undergo degranulation with release of a range of pre-formed and newly-synthesized mediators that induce a potent allergic response.

In comparison with the basophil activation test/histamine release assay this method relies on the use of donor serum/plasma.

The RBL-2H3 cells are sensitized with heat-inactivated serum from allergic patients and subsequently stimulated with a panel of allergens, where degranulation can be monitored by following the release of β-hexosaminidase as well as up-regulation of CD63 and CD203c.


This assay can primarily be used for clinical monitoring during an allergen immunotherapy treatment but also as a tool to assess allergenicity of biological compounds, cross-reactivity of food proteins, effect of processing on the allergenicity of proteins.

GBS experts can help with scientific as well as technical questions and while designing the assay the purpose of your study is always the main focus.